Skip to content
Clinical Trials – home

IRCCS Ospedale Sacro Cuore Don Calabria

Research site

Italy Via Don Angelo Sempreboni 5, 37024 Negrar di Valpolicella, Italy

  • 28 trials recruiting
  • Colitis ulcerative · Crohn's disease · Breast cancer
  • Adults and children

About Specializations

IRCCS Ospedale Sacro Cuore Don Calabria in Negrar di Valpolicella, Italy specialises in clinical trials of conditions such as Colitis ulcerative, Crohn's disease, Breast cancer, Prostate cancer, and other specialisations. This site conducts important research.

Main research areas of the site

Digestive System Diseases Research

At IRCCS Ospedale Sacro Cuore Don Calabria, clinical trials in digestive system diseases focus on ulcerative colitis, a chronic inflammatory condition of the bowel. The studies are designed to assess whether new treatments can better control symptoms, improve endoscopic findings, and support lasting remission.

  • Testing new therapies for moderately to severely active ulcerative colitis
  • Evaluating treatment effectiveness for clinical remission and symptom relief
  • Exploring longer-term benefits in ulcerative colitis care

These studies aim to expand options for patients who need more effective and durable control of intestinal inflammation.

Neoplasms and Prostate Cancer Studies

Research in neoplasms at this site includes trials in prostate cancer, especially high-risk localized or locally advanced disease and oligometastatic prostate cancer. The main goal is to determine whether new treatment approaches can improve disease control and delay progression.

  • Assessing therapies for high-risk localized prostate cancer
  • Studying treatment strategies for oligometastatic prostate cancer
  • Measuring outcomes such as metastasis-free survival and recurrence delay

These trials combine oncology expertise with a focus on improving long-term outcomes for men facing aggressive or early spread of prostate cancer.

Cardiovascular Diseases and Stroke Prevention

The site is also active in cardiovascular diseases, with trials centered on preventing another ischemic stroke after a recent event or a high-risk transient ischemic attack. The research is evaluating whether newer antithrombotic approaches can lower the risk of recurrent stroke while maintaining safety.

  • Preventing recurrent ischemic stroke after acute events
  • Studying patients with high-risk transient ischemic attack
  • Balancing stroke reduction with bleeding safety

These studies are important for refining secondary prevention strategies in patients at elevated risk of future vascular events.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Via Don Angelo Sempreboni 537024 Negrar di ValpolicellaItaly
Recruiting now
28 trials
Conditions studied
39

More sites in Negrar di ValpolicellaItaly

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

71 clinical trials

Obesity+2

Recruiting

Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:POLYPEPTIDE CONSISTING OF A GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST AND AN AMYLIN RECEPTOR AGONIST, CONNECTED BY A LINKER WITH 4 GLYCINE RESIDUES, AND CONNECTED TO A C18 FATTY ACID SIDE CHAIN
  • Sponsor:Novo Nordisk A/S
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

Long‑Term Safety and Efficacy of SPY001-001, SPY002 and SPY003 in Adults with Ulcerative Colitis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:SPY002
  • Sponsor:Spyre Therapeutics Inc.

A Study of Long-acting Antibodies SPY001-001 and SPY002 Alone and Combined for Adults with Moderate to Severe Ulcerative Colitis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:SPY002
  • Sponsor:Spyre Therapeutics Inc.

Study of Lutetium-177-DOTA-TATE with octreotide LAR in newly diagnosed patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NET) with high disease burden

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dimeticone
  • Sponsor:Novartis Pharma AG

Crohn's disease

Recruiting

Study of tulisokibart compared to placebo in adults with moderate to severe Crohn's disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Tulisokibart
  • Sponsor:Merck Sharp & Dohme LLC

Breast cancer

Recruiting

Study on the Safety and Effectiveness of Trastuzumab Deruxtecan vs. Palbociclib-Based Drug Combination for Advanced HR-Positive, HER2-Low Breast Cancer Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Medica Scientia Innovation Research S.L.

Crohn's disease

Recruiting

Study on the Effectiveness and Safety of RO7790121 for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:RO7790121
  • Sponsor:F. Hoffmann-La Roche AG

Crohn's disease

Recruiting

Study on the Effectiveness and Safety of Obefazimod for Patients with Moderate to Severe Crohn's Disease After Inadequate Response to Other Treatments

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Obefazimod
  • Sponsor:Abivax

Crohn's disease

Recruiting

Study on the Effects of MORF-057 for Adults with Moderate to Severe Crohn's Disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:MORF-057
  • Sponsor:Morphic Therapeutic Inc.

Crohn's disease

Recruiting

Efficacy and safety of ontunisertib in patients with fibrostenosing Crohn’s disease: a phase 2b randomized, double‑blind, placebo‑controlled dose‑ranging trial

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:ORG-129
  • Sponsor:Agomab Spain S.L.U.

Efficacy and Safety of JNJ-78934804 (guselkumab and golimumab) in Adults with Moderately to Severely Active Ulcerative Colitis

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.